Back to News
Market Impact: 0.22

AIM ImmunoTech Secures Europe, U.K. Patent Protection For Ampligen In Long COVID; Shares Jump

Source: Nasdaq

Patents & Intellectual PropertyHealthcare & BiotechCompany Fundamentals

AIM ImmunoTech secured European and U.K. patent protection for Ampligen (rintatolimod) for Long COVID, with exclusivity expected to run through June 2041. The development strengthens IP durability for its Long COVID program and should be supportive of longer-term commercial optionality.

AllMind Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Trial

Market Sentiment

Overall Sentiment

mildly positive

Sentiment Score

0.35

Ticker Sentiment

AIM0.65

More News

From AllMind Research

Browse all research